For more than 20 years, Alex has been working with Canada’s health technology assessment systems, both from the public and private sector. Before joining the pharmaceutical industry in 2019, Alex was the Director of CDA’s pan-Canada Oncology Drug Review (pCODR) program. Prior to that she was a Clinical Epidemiologist with Health Quality Ontario and the Ontario Health Technology Advisory Committee (OHTAC).
Day 1 Oct 28, 2025
11:50 am
Panel
The Canadian market access landscape is rapidly evolving due to shifting government policies, payer dynamics, and the complexity of biopharmaceutical innovation. This session will explore key trends, including pricing and policy changes, data-driven decision-making, new funding models, equity in access and digital health solutions, while highlighting opportunities for industry stakeholder collaboration to enhance patient access.
- Impact of Pricing and Policy Changes within Canada/US, Globally,
- Navigating evidence demands for high-cost therapies and rare disease treatments, leveraging real-world evidence,
- health outcomes data, and patient-reported outcomes to meet payer evidence demands.
- Data-Driven Decision Making and the growing importance of economic modeling and burden-of-illness studies ,
- Equity of access and digital health solutions and value-based reimbursement models exploring opportunities for collaboration between industry stakeholders to improve patient access
Day 2 Oct 29, 2025
